−2.42HKD
−423.16 MHKD
792.19 MHKD
89.55 M
About BIOCYTOGEN PHARMACEUTICALS (BEIJING
Sector
CEO
Yue Lei Shen
Website
Headquarters
Beijing
Employees (FY)
1.07 K
Founded
2009
ISIN
CNE100005D27
FIGI
BBG01998SR48
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. It operates through the following segments: Gene Editing Services, Pre-Clinical Pharmacology and Efficacy Evaluation, Animal Models Selling, Antibody Development, and Innovative Drugs Development. The Gene Editing Services segment provides gene editing services. The Pre-Clinical Pharmacology and Efficacy Evaluation segment involves in the provision of pre-clinical pharmacology service for drug efficacy and toxicity evaluation. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment includes one-stop solution from antibody preparation to IND filing for the customer. The Innovative Drugs Development consists of research and developing drugs with a focus on oncology and autoimmune disease therapeutics. The company was founded by Yue Lei Shen on November 13, 2009 and is headquartered in Beijing, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 2315 is 7.90 HKD — it has increased by 1.28% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange BIOCYTOGEN PHARMACEUTICALS (BEIJING stocks are traded under the ticker 2315.
BIOCYTOGEN PHARMACEUTICALS (BEIJING is going to release the next earnings report on Aug 27, 2024. Keep track of upcoming events with our Earnings Calendar.
2315 stock is 4.44% volatile and has beta coefficient of 0.51. Check out the list of the most volatile stocks — is BIOCYTOGEN PHARMACEUTICALS (BEIJING there?
2315 earnings for the last quarter are −0.52 HKD per share, whereas the estimation was −0.44 HKD resulting in a −17.07% surprise. The estimated earnings for the next quarter are −0.48 HKD per share. See more details about BIOCYTOGEN PHARMACEUTICALS (BEIJING earnings.
BIOCYTOGEN PHARMACEUTICALS (BEIJING revenue for the last quarter amounts to 353.20 M HKD despite the estimated figure of 339.17 M HKD. In the next quarter revenue is expected to reach 404.55 M HKD.
Yes, you can track BIOCYTOGEN PHARMACEUTICALS (BEIJING financials in yearly and quarterly reports right on TradingView.
2315 stock has risen by 16.18% compared to the previous week, the month change is a 12.22% fall, over the last year BIOCYTOGEN PHARMACEUTICALS (BEIJING has showed a 68.53% decrease.
2315 net income for the last quarter is −208.66 M HKD, while the quarter before that showed −214.66 M HKD of net income which accounts for 2.80% change. Track more BIOCYTOGEN PHARMACEUTICALS (BEIJING financial stats to get the full picture.
Today BIOCYTOGEN PHARMACEUTICALS (BEIJING has the market capitalization of 3.11 B, it has decreased by 13.46% over the last week.
No, 2315 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 2315 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOCYTOGEN PHARMACEUTICALS (BEIJING stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 1.07 K employees. See our rating of the largest employees — is BIOCYTOGEN PHARMACEUTICALS (BEIJING on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOCYTOGEN PHARMACEUTICALS (BEIJING technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOCYTOGEN PHARMACEUTICALS (BEIJING stock shows the neutral signal. See more of BIOCYTOGEN PHARMACEUTICALS (BEIJING technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on BIOCYTOGEN PHARMACEUTICALS (BEIJING future price: according to them, 2315 price has a max estimate of 16.26 HKD and a min estimate of 14.51 HKD. Read a more detailed BIOCYTOGEN PHARMACEUTICALS (BEIJING forecast: see what analysts think of BIOCYTOGEN PHARMACEUTICALS (BEIJING and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOCYTOGEN PHARMACEUTICALS (BEIJING EBITDA is −141.50 M HKD, and current EBITDA margin is −17.78%. See more stats in BIOCYTOGEN PHARMACEUTICALS (BEIJING financial statements.